Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo

Abstract

This study evaluated the effects of a mammalian target of mTOR inhibitor everolimus alone or in combination with trastuzumab on stem cells from HER2-overexpressing primary breast cancer cells and the BT474 breast cancer cell line in vitro and in vivo. For the in vitro studies, we sorted ESA+CD44+CD24−/low cells as stem cells from primary breast cancer cells… (More)
DOI: 10.1007/s13277-012-0383-6

Topics

8 Figures and Tables